Rituximab in Membranous Nephropathy

RITERM study group

Research output: Contribution to journalReview articlepeer-review

Abstract

Membranous nephropathy (MN) is the most common cause of primary nephrotic syndrome among adults. The identification of phospholipase A2 receptor (PLA2R) as target antigen in most patients changed the management of MN dramatically, and provided a rationale for B-cell depleting agents such as rituximab. The efficacy of rituximab in inducing remission has been investigated in several studies, including 3 randomized controlled trials, in which complete and partial remission of proteinuria was achieved in approximately two-thirds of treated patients. Due to its favorable safety profile, rituximab is now considered a first-line treatment option for MN, especially in patients at moderate and high risk of deterioration in kidney function. However, questions remain about how to best use rituximab, including the optimal dosing regimen, a potential need for maintenance therapy, and assessment of long-term safety and efficacy outcomes. In this review, we provide an overview of the current literature and discuss both strengths and limitations of “the new standard.”

Original languageEnglish (US)
Pages (from-to)881-893
Number of pages13
JournalKidney International Reports
Volume6
Issue number4
DOIs
StatePublished - Apr 2021

Keywords

  • B cells
  • membranous nephropathy
  • nephrotic syndrome
  • rituximab

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Rituximab in Membranous Nephropathy'. Together they form a unique fingerprint.

Cite this